A phase i study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities

Acta Oncologica

Volumn 54, Issue 8, 2015, Pages 1195-1201

  Haas, Rick L M ^a   Gelderblom, Hans ^b   Sleijfer, Stefan ^c   Van Boven, Hester H ^a   Scholten, Astrid ^a   Dewit, Luc ^a   Borst, Gerben ^a   Van Der Hage, Jos ^a   Kerst, J Martijn ^a   Nout, Remi A ^b   Hartgrink, Henk H ^b   De Pree, Ilse ^c   Verhoef, Cornelis ^c   Steeghs, Neeltje ^a   Van Coevorden, Frits ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PAZOPANIB; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EXTREMITY SOFT TISSUE SARCOMA; FATIGUE; FEMALE; HAIR DISCOLORATION; HUMAN; HYPERTENSION; LIVER TOXICITY; MALE; MIDDLE AGED; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION FIELD; RASH; RECOMMENDED DRUG DOSE; SKIN TOXICITY; SOFT TISSUE SARCOMA; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; YOUNG ADULT; ADJUVANT CHEMORADIOTHERAPY; CLINICAL TRIAL; LIMB; MAXIMUM TOLERATED DOSE; NEOADJUVANT THERAPY; PROCEDURES; SARCOMA; SOFT TISSUE NEOPLASMS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CHEMORADIOTHERAPY, ADJUVANT; EXTREMITIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; PYRIMIDINES; SARCOMA; SOFT TISSUE NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84938991271     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1037404     Document Type: Article

References (28)

1. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: A randomised trial. Lancet 2002;359:2235-41.
2. Haas RL, Delaney TF, O'Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: Why, when, and where? Int J Radiat Oncol Biol Phys 2012;84:572-80.
3. Wong G, Mehta MP. Combined chemoradiotherapy advances. Cancer Treat Res 2008;139:281-305.
4. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13:871-82.
5. Verweij J, Sleijfer S. Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother 2013;14: 929-35.
6. Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007;12:465-77.
7. Goyal S, Shah S, Khan AJ, Danish H, Haffty BG. Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib. ISRN Oncol 2012;2012:896202.
8. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32.
9. Kasper B, Sleijfer S, Litiere S, Marreaud S, Verweij J, Hodge RA, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 2014;25:719-24.
10. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
11. Kapadia S, Hapani S, Choueiri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 2013;52:1202-12.
12. Shah D, Borys D, Martinez SR, Li CS, Tamurian RM, Bold RJ, et al. Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma. Anticancer Res 2012;32:3911-5.
13. Canter RJ, Martinez SR, Tamurian RM, Wilton M, Li CS, Ryu J, et al. Radiographic and histologic response to neoad-juvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol 2010;17:2578-84.
14. Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 2014;111:1909-16.
15. Sleijfer S, Gorlia T, Lamers C, Burger H, Blay JY, Le Cesne A, et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: An EORTC-STBSG study. Br J Cancer 2012;107:639-5.
16. Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, et al. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2014;21:1616-23.
17. Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2011;81:1081-90.
18. Jakob J, Rauch G, Wenz F, Hohenberger P. Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma. Br Med J Open 2013; 3:e003626.
19. Sleijfer S, Gelderblom H. Current clinical trials for advanced osteosarcoma and soft tissue sarcoma. Curr Opin Oncol 2014;26:434-9.
20. Betgen A, Haas RL, Sonke JJ. Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. J Radiat Oncol 2013;2:55-62.
21. de Vreeze RS, de Jong D, Haas RL, Stewart F, van Coevorden F. Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern. Int J Radiat Oncol Biol Phys 2008;72:1480-7.
22. O'Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer 2013;119:1878-84.
23. Schwartz A, Rebecca A, Smith A, Casey W, Ashman J, Gunderson L, et al. Risk factors for significant wound complications following wide resection of extremity soft tissue sarcomas. Clin Orthop Relat Res 2013;471:3612-7.
24. Nielsen OS, Cummings B, O'Sullivan B, Catton C, Bell RS, Fornasier VL. Preoperative and postoperative irradiation of soft tissue sarcomas: Effect of radiation field size. Int J Radiat Oncol Biol Phys 1991;21:1595-9.
25. Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer 2014;111:2254-61.
26. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
27. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
28. Vlenterie M, van Erp NP, van der Graaf WT. Promising management of pazopanib-induced liver toxicity. Acta Oncol Epub 2015 Mar 3:1-3.